The effect of thromboxane A2 (TXA2) synthase inhibitor (Ozagrel) on difficult to treat chough variant asthma (CVA). - The effect of Ozagrel on difficult to treat cough variant asthma.

Start Date22 Oct 2014

Sponsor / Collaborator-

CTRI/2012/05/002644 / RecruitingPhase 4IIT

Randomized double blind placebo controlled trial of Sodium ozagrel and Edaravone in acute ischemic stroke - EDOZ

Start Date05 Mar 2012

Sponsor / Collaborator

Jawaharlal Institute of Post Graduate Medical Education & Re

NCT02503176 / TerminatedPhase 3

An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

The purpose of this study is to evaluate of the long-term safety and efficacy of KCT-0809 in dry eye patients with Sjögren's syndrome.

Start Date-

Sponsor / Collaborator

Kissei Pharmaceutical Co., Ltd.

100 Clinical Results associated with Ozagrel Sodium

100 Translational Medicine associated with Ozagrel Sodium

100 Patents (Medical) associated with Ozagrel Sodium

Literatures (Medical) associated with Ozagrel Sodium

01 Sep 2024·No shinkei geka. Neurological surgery

[Postoperative Management of Aneurysmal Subarachnoid Hemorrhage].

Review

Author: Endo, Hidenori ; Sakata, Hiroyuki

Delayed cerebral ischemia(DCI) is one of the most significant complications of subarachnoid hemorrhage. Despite significant evolution in understanding DCI pathophysiology, vasospasm affecting cerebral vessels of large and moderate diameters remain the only clinically measurable component of DCI and is therefore the primary target for intervention in the postoperative management of subarachnoid hemorrhage. In Japan, fasudil hydrochloride and ozagrel sodium are widely used to prevent vasospasms; however, their effects are sometimes insufficient. Clazosentan, a selective endothelin receptor subtype A antagonist, reduces vasospasm-related morbidity and all-cause mortality following aneurysmal subarachnoid hemorrhage. This was demonstrated in a recent randomized phase 3 trial, leading to the approval of clazosentan by the Pharmaceuticals and Medical Devices Agency in Japan. Recent advances in our understanding of subarachnoid hemorrhage will facilitate improved management to reduce the incidence of DCI.

01 Jan 2024·Advances in Experimental Medicine and Biology

Preventing Fluid Retention After Subarachnoid Haemorrhage During Administration of Endothelin Receptor Antagonist

Article

Author: Shimoda, Kentaro ; Hirahata, Shinobu ; Okuma, Yu ; Kido, Goro ; Kagawa, Yukihide ; Suzuki, Kazumoto ; Tanda, Akane

Prevention of delayed cerebral infarction (DCI) due to cerebral vasospasm after subarachnoid haemorrhage (SAH) has been done with intravenous Rho kinase inhibitors (ROCKI), ozagrel sodium (TXA2I), selective ROCKI infusion (ROCKI i.a.), and cerebrospinal fluid (CSF) drainage. The endothelin receptor antagonist (ERA, clazosentan) became available in 2022 and is said to be highly recommended for DCI prevention, while fluid retention such as pleural effusion and pulmonary oedema accumulation is often experienced. We investigated the relationship between patient background, fluid retention, and ERA. Ten consecutive SAH patients treated with ERA from July to December 2022 were included. We examined the results of blood sampling on admission, echocardiography, chest computed tomography (CT), with postoperative DCI, and hydrocephalus requiring cerebrospinal fluid shunt (hydro), and symptomatic fluid retention requiring albumin and furosemide (third fluid space). Two males and eight females, mean age 63 years, mean preoperative World Federation Neurosurgical Surgeons (WFNS) grade 3.5, mean creatinine 0.94, mean brain natriuretic peptide (NT-proBNP). In 1883, two patients with Takotsubo cardiomyopathy and four patients with neurogenic pulmonary oedema are present. All patients underwent coil embolisation, and postoperative CSF drainage, ROCKI, TXA2I systemic administration, and ROCKI i.a. There were one DCI, three hydro, and five third fluid cases. Concerning the third fluid, the only significant difference was found in the age. An improvement in fluid retention after ERA discontinuation in old patients was shown. Our experience suggests that age may be the most influential factor. Based on these results, we have also found that by avoiding the use of ERA in patients older than 80 years, strictly limiting the infusion volume when using ERA, and actively using the drugs for heart failure early on, the frequency of suffering from third fluid space is reduced.

01 Jan 2022·Clinical and experimental vaccine research

Thalamic hemi-chorea: a rare complication after receiving the adenoviral vector-based COVID-19 vaccine: a case report

Author: Asgari, Ali ; Shahali, Hamze ; Hazrati, Ebrahim ; Farahani, Ramin Hamidi

Lacunar strokes occur when a branch of a large cerebral artery is blocked. The thalamus is often affected, causing uncontrollable motions. A 72-year-old previously healthy man presented with involuntary motions in the right limbs, which were present at rest, and exacerbated during voluntary actions. He had received the first dose of the adenoviral vector-based coronavirus disease 2019 vaccine (ChAdOx1 nCoV-19) 9 days ago. Severe thrombocytopenia and elevated levels of lactate dehydrogenase, ferritin, C-reactive protein, and D-dimer were found, without any evidence of connective tissue disease. Electromyography demonstrated typical choreiform movements, and the brain magnetic resonance imaging indicated a small high signal lesion on the left side of the thalamus. Detection of the immunoglobulin G antibodies against platelet factor 4 in the blood, negative heparin-induced platelet activation (HIPA) test, and positive modified HIPA test confirmed the thalamic stroke due to the vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). He was admitted to the intensive care unit and received nadroparin, sodium ozagrel, edaravone, methylprednisolone, and haloperidol. His hemi-chorea improved gradually over 2 weeks, and he was discharged after 21 days with rehabilitation advice. VIPIT due to the ChAdOx1 nCoV-19 is a novel immune-mediated response that needs clinicians' awareness and further investigations.

News (Medical) associated with Ozagrel Sodium

24 Nov 2016

·www.bioportfolio.com

Hybio Pharmaceutical Co., Ltd. 300199 Financial and Strategic SWOT Analysis Review Prices from USD $300

Summary Hybio Pharmaceutical Co., Ltd. Hybio is a biopharmaceutical company that develops polypeptide drugs. The company manufactures and develops peptide finished dosage products and peptide active pharmaceutical ingredients. Its finished dosage products include desmopressin for injection, terlipressin for injection, sodium ozagrel for injection, oxytocin for injection, omeprazole sodium for injection,and others. Hybio provides active pharmaceutical ingredients such as abarelix, calcitonin, copaxone, antide, desmopression, alarelin, bivalirudin, desirudin, elecatonin, fertirelin, ganadorelin, histrelin, leuprorelin, vapreotide and haxapeptide. The company conducts research and development to advance its products. Hybio is headquartered in Shenzhen, China. This comprehensive SWOT profile of Hybio Pharmaceutical Co., Ltd. provides you an indepth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. This company report forms part of GlobalData's Profile on Demand' service, covering over 50,000 of the world's leading companies. Once purchased, GlobalData's highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Hybio Pharmaceutical Co., Ltd. including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. excluding weekends. The profile contains critical company information including*, x000D x000D Business description A detailed description of the company's operations and business divisions.x000D Corporate strategy Analyst's summarization of the company's business strategy.x000D SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.x000D Company history Progression of key events associated with the company.x000D Major products and services A list of major products, services and brands of the company.x000D Key competitors A list of key competitors to the company.x000D Key employees A list of the key executives of the company.x000D Executive biographies A brief summary of the executives' employment history.x000D Key operational heads A list of personnel heading key departments/functions.x000D Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.x000D Key manufacturing facilities A list of key manufacturing facilities of the company.x000D Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.x000D Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.x000D x000D Note*: Some sections may be missing if data is unavailable for the company. Key benefits of buying this profile include,x000D x000D You get detailed information about the company and its operations to identify potential customers and suppliers.x000D The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.x000D x000D Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.x000D The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events. x000D x000D Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.x000D Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.x000D x000D Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.x000D Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.x000D x000D Gain key insights into the company for academic or business research.x000D Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Financial StatementAcquisition

100 Deals associated with Ozagrel Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D01684	Ozagrel Sodium	C	DB12017

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cerebrovascular Disorders	CN	Dan Dong Yi Chuang Yao Ye You Xian Ze Ren Gong Si	01 Jan 1997
Thrombosis of cerebral veins	JP	Maruishi Pharmaceutical Co., Ltd.	21 Jan 1992
Subarachnoid Hemorrhage	JP	Maruishi Pharmaceutical Co., Ltd.	20 Jan 1988

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sjogren's Syndrome	Phase 3	JP	Kissei Pharmaceutical Co., Ltd.	20 Jul 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis